AU2010203425B2 - Therapeutic compositions for treatment of corneal disorders - Google Patents

Therapeutic compositions for treatment of corneal disorders Download PDF

Info

Publication number
AU2010203425B2
AU2010203425B2 AU2010203425A AU2010203425A AU2010203425B2 AU 2010203425 B2 AU2010203425 B2 AU 2010203425B2 AU 2010203425 A AU2010203425 A AU 2010203425A AU 2010203425 A AU2010203425 A AU 2010203425A AU 2010203425 B2 AU2010203425 B2 AU 2010203425B2
Authority
AU
Australia
Prior art keywords
corneal
receptor
composition
nerve
cytokine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2010203425A
Other languages
English (en)
Other versions
AU2010203425A1 (en
Inventor
Sunil Chauhan
Reza Dana
Mohammed Dastjerdi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
The Schepens Eye Research Institute Inc
Original Assignee
The Schepens Eye Research Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Schepens Eye Research Institute Inc filed Critical The Schepens Eye Research Institute Inc
Publication of AU2010203425A1 publication Critical patent/AU2010203425A1/en
Application granted granted Critical
Publication of AU2010203425B2 publication Critical patent/AU2010203425B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2006—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Plant Pathology (AREA)
  • Endocrinology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2010203425A 2009-01-09 2010-01-11 Therapeutic compositions for treatment of corneal disorders Ceased AU2010203425B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14356109P 2009-01-09 2009-01-09
US61/143,561 2009-01-09
PCT/US2010/020646 WO2010081091A2 (en) 2009-01-09 2010-01-11 Therapeutic compositions for treatment of corneal disorders

Publications (2)

Publication Number Publication Date
AU2010203425A1 AU2010203425A1 (en) 2011-07-28
AU2010203425B2 true AU2010203425B2 (en) 2015-04-09

Family

ID=42144303

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010203425A Ceased AU2010203425B2 (en) 2009-01-09 2010-01-11 Therapeutic compositions for treatment of corneal disorders

Country Status (6)

Country Link
US (1) US10117906B2 (cg-RX-API-DMAC7.html)
EP (1) EP2385839B1 (cg-RX-API-DMAC7.html)
JP (1) JP2012515164A (cg-RX-API-DMAC7.html)
AU (1) AU2010203425B2 (cg-RX-API-DMAC7.html)
CA (1) CA2749537C (cg-RX-API-DMAC7.html)
WO (1) WO2010081091A2 (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20230776T1 (hr) * 2010-07-29 2023-10-27 Buzzard Pharmaceuticals AB Himerni antagonisti receptora il-1 tipa i
WO2012103240A2 (en) * 2011-01-25 2012-08-02 Eleven Biotherapeutics, Inc. Receptor binding agents
WO2013126599A1 (en) 2012-02-21 2013-08-29 Massachusetts Eye & Ear Infirmary Meibomian gland dysfunction
WO2013126602A1 (en) 2012-02-21 2013-08-29 Massachusetts Eye & Ear Infirmary Inflammatory eye disorders
WO2014036445A2 (en) * 2012-08-31 2014-03-06 Johnson Michael R Novel mucolytic agents
JP6450364B2 (ja) 2013-03-13 2019-01-09 セセン バイオ, インコーポレイテッド 眼送達のためのキメラサイトカイン製剤
SG11201601291QA (en) 2013-08-23 2016-03-30 Parion Sciences Inc Dithiol mucolytic agents
JP6377618B2 (ja) * 2013-08-28 2018-08-22 千寿製薬株式会社 角膜上皮障害治療剤
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
BR112017016067A2 (pt) 2015-01-30 2018-04-03 Parion Sciences Inc agentes mucolíticos de monotiol
JP2018520986A (ja) 2015-04-30 2018-08-02 パリオン・サイエンシィズ・インコーポレーテッド ジチオール粘液溶解剤の新規なプロドラッグ
US20180312838A1 (en) * 2015-10-21 2018-11-01 The Regents Of The University Of California Modulation of microrna 184 to treat pathological lymphangiogenesis
WO2018231827A1 (en) 2017-06-12 2018-12-20 Bluefin Biomedicine, Inc. Anti-il1rap antibodies and antibody drug conjugates
WO2020218488A1 (ja) * 2019-04-26 2020-10-29 千寿製薬株式会社 眼疾患マーカー
CN113350326B (zh) * 2021-07-28 2023-03-17 爱尔眼科医院集团股份有限公司 化合物lm22b-10在制备角膜上皮及神经损伤治疗药物中的应用
KR102883890B1 (ko) * 2021-11-30 2025-11-07 한림대학교 산학협력단 miR-30c-1 발현 수준을 증가시키기 위한 제제를 사용하는 각막 내피 세포 배양 방법 및 각막 내피 세포 질환 치료용 조성물
CN118304388B (zh) * 2024-04-03 2025-02-11 南通大学 Tak1在制备治疗周围神经损伤药物中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040208874A1 (en) * 2002-12-30 2004-10-21 Khare Sanjay D. Combination therapy with co-stimulatory factors

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0610336B1 (en) 1991-10-31 2002-03-27 The Victoria University Of Manchester Treatment of neurological conditions by an interleukin-1 inhibiting compound
US5900407A (en) * 1997-02-06 1999-05-04 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with uridine triphosphates and related compounds
US6974682B1 (en) 1996-08-26 2005-12-13 Human Genome Sciences, Inc. Soluble interleukin-1 receptor accessory molecule
WO1998022130A1 (en) * 1996-11-19 1998-05-28 The Schepens Eye Research Institute, Inc. Local use of il-1ra in corneal transplant rejection or disorders of the eye
US6337072B1 (en) 1998-04-03 2002-01-08 Hyseq, Inc. Interleukin-1 receptor antagonist and recombinant production thereof
US6927044B2 (en) 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
JP3363832B2 (ja) 1999-05-13 2003-01-08 アルプス電気株式会社 薄膜構造体およびその製造方法
US20030104041A1 (en) 1999-12-16 2003-06-05 Tsung-Min Hsu Transdermal and topical administration of drugs using basic permeation enhancers
EP1252895A4 (en) 2000-01-31 2003-04-16 Santen Pharmaceutical Co Ltd REMEDIES FOR OPHTHALMIC DISORDERS
WO2001057082A2 (en) 2000-02-03 2001-08-09 Regeneration Technologies, Inc. Extraction of growth factors from tissue
US20010047204A1 (en) * 2000-03-20 2001-11-29 Medennium, Inc. Method for determination of a properly sized posterior chamber phakic refractive lens
US20020131954A1 (en) 2000-05-02 2002-09-19 Tobinick Edward L. Interleukin antagonists for the treatment of neurological, retinal and muscular disorders
US20030026806A1 (en) 2000-10-27 2003-02-06 Amgen Inc. Antibodies and other selective IL-1 binding agents that allow binding to IL-1 receptor but not activation thereof
US20050143333A1 (en) 2001-05-18 2005-06-30 Sirna Therapeutics, Inc. RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (SINA)
WO2003022213A2 (en) 2001-09-06 2003-03-20 Board Of Regents, The University Of Texas System Therapeutic treatments for spinal cord injury via blockade of interleukin-1 receptor
US7683165B2 (en) 2002-02-20 2010-03-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (siNA)
US6890654B2 (en) 2002-04-18 2005-05-10 Northwestern University Encapsulation of nanotubes via self-assembled nanostructures
US20050196370A1 (en) * 2003-03-18 2005-09-08 Zhi-Jian Yu Stable ophthalmic oil-in-water emulsions with sodium hyaluronate for alleviating dry eye
US20050033694A1 (en) * 2003-06-03 2005-02-10 United States Postal Service. System and method for fleet card management
US7261882B2 (en) 2003-06-23 2007-08-28 Reagents Of The University Of Colorado Methods for treating neuropathic pain by administering IL-10 polypeptides
US20050023872A1 (en) * 2003-07-28 2005-02-03 Hetzel Thomas R. Modular seat cushion with interlocking human support and base portions and method of creating and using a seat cushion
KR100543466B1 (ko) * 2003-11-13 2006-01-20 삼성전자주식회사 영상 보간 장치 및 방법
GB0404693D0 (en) 2004-03-02 2004-04-07 Univ London Pharmaceutical preparations for the treatment of ocular surface and other disorders
US8618054B2 (en) 2004-05-05 2013-12-31 Valorisation-Rechereche Société en Commandite Interleukin-1 receptor antagonists, compositions, and methods of treatment
US8541413B2 (en) 2004-10-01 2013-09-24 Ramscor, Inc. Sustained release eye drop formulations
CA2588449A1 (en) * 2004-11-24 2006-06-01 Therakine Corporation An implant for intraocular drug delivery
JP4815808B2 (ja) 2005-01-24 2011-11-16 三菱電機株式会社 ロータリ圧縮機
CN102293774A (zh) 2005-03-31 2011-12-28 旭硝子株式会社 前列腺素F2α衍生物的应用
EP1870099A4 (en) 2005-04-13 2008-07-16 Ube Industries PROTECTION AGAINST RETINAL NERVOUS CELLS WITH INDAZOLE DERIVATIVE AS ACTIVE SUBSTANCE
US7670849B2 (en) 2005-04-29 2010-03-02 Henkin Robert I Method for diagnosing insulin resistance from nasal secretions
DE602006009834D1 (de) * 2005-09-01 2009-11-26 Schering Corp Verwendung von il-23 und il-17-antagonisten zur behandlung von autoimmuner entzündlicher augenerkrankung
KR20110079922A (ko) * 2006-04-14 2011-07-11 노파르티스 아게 안과 장애 치료를 위한 il-1 항체의 용도
US20080026485A1 (en) * 2006-04-18 2008-01-31 Wolfgang Hueber Antibody profiling for determination of patient responsiveness
CN101489569A (zh) 2006-06-12 2009-07-22 席拉坎有限责任公司 眼表面疾病的局部治疗
CA2679588A1 (en) * 2007-03-26 2008-10-02 Zymogenetics, Inc. Soluble il-17ra/rc fusion proteins and related methods
US8399421B2 (en) 2007-03-30 2013-03-19 The Board Of Regents Of The University Of Texas System Treatment for neuropathic pain due to spinal cord injury
EP2187900B1 (en) 2007-08-16 2016-11-09 The Schepens Eye Research Institute, Inc. Therapeutic compositions for treatment of inflammation of ocular and adnexal tissues
CA2711696C (en) * 2008-01-09 2021-10-26 Reza Dana Therapeutic compositions for treatment of ocular inflammatory disorders
US20120014970A1 (en) * 2009-01-09 2012-01-19 Reza Dana Therapeutic Compositions for Treatment of Corneal Disorders
US9011861B2 (en) * 2010-02-25 2015-04-21 Schepens Eye Research Institute Therapeutic compositions for the treatment of dry eye disease

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040208874A1 (en) * 2002-12-30 2004-10-21 Khare Sanjay D. Combination therapy with co-stimulatory factors

Also Published As

Publication number Publication date
WO2010081091A3 (en) 2010-11-18
US20100183587A1 (en) 2010-07-22
AU2010203425A1 (en) 2011-07-28
CA2749537A1 (en) 2010-07-15
CA2749537C (en) 2018-11-20
WO2010081091A2 (en) 2010-07-15
JP2012515164A (ja) 2012-07-05
US10117906B2 (en) 2018-11-06
EP2385839B1 (en) 2014-11-26
EP2385839A2 (en) 2011-11-16

Similar Documents

Publication Publication Date Title
CA2749537C (en) Il-1 antagonist compositions for corneal nerve regeneration and protection
JP5886523B2 (ja) 眼の炎症性障害を処置するための治療組成物
US10105441B2 (en) Method for inhibiting or reducing dry eye disease by IL-1Ra
US20250195608A1 (en) Therapeutic Compositions for the Treatment of Dry Eye Disease
JP2011516400A5 (cg-RX-API-DMAC7.html)
Chucair-Elliott et al. IL-6 contributes to corneal nerve degeneration after herpes simplex virus type I infection
US20120014970A1 (en) Therapeutic Compositions for Treatment of Corneal Disorders
Gagliano et al. Intravitreal steroids for the prevention of PVR after surgery for retinal detachment
JP6440107B2 (ja) 細胞シートの製造方法、組成物、細胞培養補助剤、及び細胞培養方法
AU2017205185B2 (en) Therapeutics for ocular immunoinflammatory diseases
CA2640986C (en) Therapeutic compositions for treatment of inflammation of ocular and adnexal tissues
CN114206849A (zh) 用于治疗非感染性眼部免疫炎性病症的治疗方法
AU2014227534B2 (en) Therapeutic compositions for treatment of inflammation of ocular and adnexal tissues

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired